Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Cysteamine for Postinflammatory Hyperpigmentation
NCT05206318Unknown
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Dec 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in Post-inflammatory hyperpigmentation (PIH) comparing Topical Cysteamine with Vehicle Control (2 arms). Primary endpoint: Change from Baseline Pigmentation at 16 weeks. Status: unknown.
02
Drugs
cysteamine
03
Conditions
Post-inflammatory hyperpigmentation (PIH)
Beyond the preview
Go deeper on NCT05206318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05206318.